Get all premium features to the best stock analysis tool

Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer

Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles

Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial

Company on track to initiate SOTERIA trial in the second half of 2026 Clinical development activities advancing following FDA authorization, CRO engagement and Fast Track Designation across all four planned indication PARAMUS, NJ, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders (“LSDs”), today provided an operational readiness update for SOTERIA, its Phase 2 basket trial evaluating lead candidate PLX-200 across four rare pediatric LSDs. Polaryx continues to advance clinical trial start-up activities in collaboration with its contract research organization (CRO) and remains focused on initiating SOTERIA in the fourth quarter of 2026.